PROJECT ON LUPIN PHRMA

INDEX

S.NO CONTENT PAGE NO

1 COMPANY OVERVIEW 3

2 PRODUCT OVERVIEW 6

3 FACTORS AFFECTING SUPPLY

8

4 FACTORS AFFECTING DEMAND

10

5 MARKET SURVEY 12

6 RESPONSE OF CONSUMER 13

7 OBSERVVATION 14

8 DEMAND SCHEDULE 15

9 TYPE OF COMPETITION 16

10 FORM OF MARKET STRUCTURE

17

11 SHORT RUN EQUILIBRIUM 18

12 LONG RUN EQUILIBRIUM 19

13 LEVEL OF BARRIERS 20

14 AFFECT ON PRICE STRATEGY

22

15 FINANCIAL STATEMENT 23

16 CSR 29

17 BIBLIOGRAPHY 34

Company Overview

Date of Establishment 1983

Revenue 580.952 ( USD in Millions )

Market Cap 161393.894597 ( Rs. in Millions )

BnCorporate Address 159 C S T Road,KalinaSantacruz (East), Mumbai-400098, Maharashtrawww.lupinworld.com

Management Details Chairperson - DeshBandhu Gupta MD - Kamal K SharmaDirectors - D K Contractor, DeshBandhu Gupta, K U Mada, K V Kamath, K V Kamoth, Kamal K Sharma, M D Gupta, Marc Desaedeleer, Nilesh Gupta,

http://www.lupinworld.com/

R A Shah, R V Satam, Richard Zahn, Sunil Nair, Vijay Kelkar, Vinita Gupta

Business operationBackground

Pharmaceuticals & Drugs Lupin is a transnational company engaged in development of APIs, generic and branded formulations.It is the largest manufacturer of Tuberculosis drugs in the world. It has onshore and offshore presence of its products in 70 countries.

Its manufacturing unit is located in Goa, Tarapur, Ankleshwar, Jammu, Mandideep, Indore,

Key excutive

S.No Name Designation

1 DeshBandhu Gupta Chairman

3 Kamal K Sharma Managing Director

2 R V Satam Company Secretary

4 D K Contractor Director

5 Vinita Gupta Director

6 K U Mada Director

7 R A Shah Director

8 M D Gupta Executive Director

9 Nilesh Gupta Executive Director

10 Vijay Kelkar Additional Director

11 K V Kamoth Additional Director

12 Richard Zahn Additional Director

13 K V Kamath Independent Director

14 Vijay Kelkar Independent Director

15 Richard Zahn Independent Director

INTRODUCTION OF LUPIN PHARMAAbout Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company’s R&D endeavors have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 8th by prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY - IMS)

For the financial year ended March 2009, Lupin's Consolidated Revenues and Profit after Tax were Rs.39,145 million (US$ 851 million) and Rs. 5015 million (US$ 109 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

http://www.lupinworld.com/

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visithttp://www.lupinpharmaceuticals.com.

Lupin PharmaThe Company’s concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. In a Rs.3,162mn Anti-TB market, Lupin commands 48% of the market share. As market leaders in this space, Lupin has embarked on an effort which would redefine the treatment guidelines based on conditions existing in India under the aegis of RIETT-Redefining Indian Expertise Based Tuberculosis Treatment.

Key Products : LupinPharma

http://www.lupinpharmaceuticals.com/

Company Sales(Rs.Million)Current

PriceChange

(%)P/E Ratio

MarketCap.

(Rs.Million)

52-WeekHigh/Low

Sun Pharma 38615.50 1546.05 0.03 29.99 320119.09 1846/1070

Cipla 49606.00 316.75 0.06 23.49 254164.76 363/211

Dr Reddy's 41589.00 1289.90 -1.59 26.16 221305.65 1335/598

Ranbaxy Labs. 47802.86 422.90 1.54 7.89 175208.31 538/217

Glaxosmithkline

Phar18707.67 2038.00 -0.30 32.03 173149.91 2271/1086

Lupin 28985.60 1815.60 0.12 24.87 161393.89 1844/755

Cadila Healthcare 16985.00 612.00 2.84 24.21 121845.84 838/188

ProductTherapeutic segment

Product Rank in the relevant segment

R-Cinex Anti-TB 1AKT Anti-TB 1Akurit Anti-TB 1R-CIN Anti-TB 1G-CIN Gemifloxacin 1Combutol Ethambutol& Comb. 1Pyzina Pyrazinamide Plain 2

Piramal Healthcare 23162.60 500.65 -0.34 23.69 104997.75 600/250

Divi'S Lab 11905.60 721.00 4.42 34.04 91238.92 728/452

GlenmarkPharma 8545.59 271.45 3.84 44.79 70546.36 304/199

Biocon 9123.37 286.55 1.00 22.85 56740.00 311/164

Jubilant Life 24285.34 344.00 1.79 14.78 53659.62 373/155

AurobindoPharma 27948.30 882.60 2.66 10.01 48392.67 990/326

TorrentPh 11848.92 538.90 1.27 21.71 45025.94 555/164

Aventis Pharma 9744.06 1873.00 1.08 27.89 42675.74 1968/1030

Matrix Laboratories 15021.32 209.35 0.00 18.90 32729.53 227/165

Pfizer 8310.44 1050.00 0.14 22.30 31288.75 1125/711

Ipca Laboratories 12956.40 244.05 -1.09 17.19 30899.92 304/85

Ster.Biot 11783.81 112.00 0.81 16.16 27796.84 146/90

AstrazenecaPharm

a3965.06 841.00 1.41 39.15 20732.50 1109/570

Fresenius

KabiOncol2620.83 129.05 3.16 53.38 19794.28 163/42

SunPhaAdv 351.42 93.15 0.22 0.00 19251.47 105/57

Novartis 5994.80 611.15 3.22 16.32 18923.99 633/385

DishmanPharma 4158.85 221.90 0.29 21.25 17854.24 275/136

Wyeth 2863.60 785.00 1.16 29.88 17630.77 850/500

FDC 5763.62 91.50 1.95 13.60 16718.50 96/37

Strides Arcolab 7694.42 346.40 -3.27 16.57 15587.78 371/98

Abbott India 7945.57 1072.00 -2.27 19.83 15000.37 1210/415

Unichem Lab 6568.67 403.40 1.34 10.75 14357.19 453/189

Wockhardt 15038.91 121.10 0.67 0.00 13165.14 201/107

Solvay Pharma 2417.26 2519.95 3.81 28.12 12257.40 3600/650

PlethicoPharma 4721.43 351.70 0.03 15.41 11977.84 405/151

Panacea Biotec 7734.17 173.95 2.72 14.15 11319.82 248/100

Merck 4731.10 635.00 1.19 14.42 10416.94 687/371

Orchid Chemicals 11914.40 140.25 2.86 0.00 9604.78 239/78

Nectar Lifesciences 7279.68 37.85 0.00 10.70 8488.28 44/15

JB Chem&Pharma 6767.61 81.10 1.31 6.69 6753.75 96/37

Elder Pharma 6200.22 368.95 5.28 11.96 6608.61 408/218

Shilpa Medicare 1359.55 297.40 1.47 13.59 6455.28 363/64

Alembic 10940.85 47.05 1.62 29.89 6181.79 56/35

Indoco Remedies 3506.35 400.95 0.14 11.69 4919.60 442/148

NatcoPharma 2696.92 162.00 2.11 9.72 4465.67 184/71

Bliss GVS 1329.56 42.60 2.40 10.46 4290.90 51/15

Parenteral Drugs 2260.74 193.00 -2.03 14.25 3821.82 255/57

Zenotech Lab. 60.23 112.50 1.35 0.00 3821.65 139/93

Fulford India 1947.00 990.15 1.59 24.25 3801.14 1150/436

Morepen Labs 1641.04 7.90 2.33 0.00 3472.66 12/7

Ankur Drugs 9653.21 183.40 4.80 3.78 3384.78 251/100

Suven Life

Sciences1400.11 28.35 3.09 45.78 3204.75 37/18

Piramal Life

Science21.30 130.50 4.99 0.00 3163.60 152/50

Sequent Scientific 1060.62 139.95 0.14 26.57 3065.44 164/35

Zandu Realty 877.46 3540.00 -0.65 8.66 2873.40 12800/2513

Shasun Chemicals 4708.34 58.50 2.45 22.60 2758.73 72/18

TTK Healthcare 2196.47 342.00 -2.56 29.87 2725.86 435/101

Surya Pharma 7229.24 172.85 3.01 3.25 2427.79 196/75

Alchemist 3864.66 185.00 0.57 13.26 2252.43 216/82

Twilight Litaka Phar 3704.43 107.25 3.08 6.63 2214.32 132/33

Venus Remedies 2640.94 266.50 3.11 4.83 2194.75 312/182

Ajanta Pharma 3194.77 183.30 2.75 7.32 2088.80 212/73

Themis Medicare 1998.98 245.80 3.47 10.58 1912.40 301/60

Granules India 2538.74 96.50 1.85 7.94 1900.42 115/52

Amrutanjan Health 906.60 613.00 0.14 14.23 1854.81 1345/324

IndSwiLab 5834.95 66.50 2.23 3.77 1811.80 80/34

Phaarmasia 111.00 253.00 -4.99 0.00 1727.22 344/253

SMS Pharma 2445.92 167.95 2.41 71.17 1642.49 190/109

MarksansPharma 1995.30 4.35 2.35 707.32 1563.18 8/4

Vivimed Labs 1514.89 156.75 1.59 12.96 1537.58 175/65

Jupiter Bioscience 1429.28 81.95 0.43 4.90 1510.29 105/52

Aarti Drugs 3765.03 112.25 3.08 5.62 1318.62 128/48

Anu's Labs 1597.09 5.90 8.66 7.67 1311.45 27/5

Kilitch Drugs 1290.12 100.00 3.31 10.84 1277.97 157/59

Sharon Bio-

Medicine4197.91 115.00 2.68 5.30 1182.37 144/42

Kopran 1186.42 32.10 4.05 11.60 1144.62 37/9

IndSwiLtd 5870.55 29.50 1.03 3.03 1085.61 37/16

Wanbury 1672.88 72.45 1.26 0.00 1051.02 96/44

AnuhPharma 1205.13 377.85 2.29 7.97 1028.41 465/172

RPG Life Sciences 1392.43 70.80 5.12 9.40 1014.89 92/26

Bharat 71.08 18.75 3.02 0.00 785.88 26/17

Immunological

Ambal Sarabhai 625.10 10.12 1.30 4.14 765.57 17/10

Hester Biosciences 301.60 136.50 -0.73 12.14 713.79 156/76

Albert David 2056.92 124.05 1.39 6.80 698.27 143/62

Syncom Healthcare 605.65 39.20 1.29 17.07 677.25 162/39

BafnaPharma 457.99 43.60 3.20 14.19 675.21 45/19

Adinath Bio-Lab 218.18 2.86 -4.35 34.79 660.02 21/3

Lyka Labs 1520.75 29.25 2.63 26.45 615.03 41/17

DIL 17.68 263.00 5.05 7.50 574.10 309/146

JagsonpalPharma 1361.98 21.20 6.53 5.70 521.34 27/11

Neuland Lab. 3067.22 94.95 2.10 0.00 501.87 160/92

HiranOrgochem 1885.67 9.55 1.38 0.00 494.58 13/4

Kerala Ayurveda 179.85 45.35 0.00 0.00 478.70 66/30

Gufic Biosciences 515.76 6.13 3.03 36.13 460.23 11/4

Arvind Remedies 2178.88 1.73 5.49 5.75 426.48 3/1

Smruthi Organics 729.54 105.25 0.19 7.22 400.81 132/38

AhlconParenterals 378.30 54.25 0.00 9.19 390.61 58/22

Lincoln Pharma 1140.18 32.50 2.52 4.58 358.55 39/19

Celestial Biolabs 192.51 31.55 5.34 5.96 352.90 45/14

Rubra Medicaments 10.21 61.85 4.92 0.00 322.36 59/10

Syncom

Formulations575.64 26.50 4.33 6.47 315.22 34/15

Alpa Lab 1201.01 14.65 -0.68 38.94 310.35 20/11

Elder 508.08 74.35 -1.20 0.00 301.00 111/26

Maxter

As the face of Lupin in the critical care segment and Anti- Infectives, Maxter Division emulates the Company’s objective of ‘saving more lives’. As a spin-off from Endeavour, the division was launched in 2006-07. The inception of Maxter has empowered Lupin to tap unexplored opportunities in chosen therapeutic area, with an unwavering focus. This division focuses on giving the best therapeutic care in the critical care segment. It reaches out to interventionists and super-specialty doctors and has also ventured into the field of wound management.

Key Products :Maxter

Product Therapeutic segmentProduct Rank in the relevant segment

Merotrol Meropenem 1

Tazar Piperacillin + Tazobactam

1

Ceff Cephalexin Oral Solids

3

Cetil Cefuroxime Oral Solids

5

Cefantral CefotaximeInjectibles 9

PRODUCTS OF LUPIN PHARMA

LupinPharma

Brand Name Molecule Therapy Segment

AKT 2Each Kit contains RIFAMPICIN - 450 MG+ ISONIAZID - 300 MG

TUBERCULOSTATIC

AKT3Each Kit contains RIFAMPICIN - 450 MG + ISONIAZID - 300 MG+ ETHAMBUTOL - 800 MG

TUBERCULOSTATIC

AKT4 Each Kit contains RIFAMPICIN - TUBERCULOSTATIC

450 MG + ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG + PYRAZINAMIDE - 1500 MG

AKT FD

Each tablet contains RIFAMPICIN - 150 MG+ISONIAZID -100 MG + ETHAMBUTOL - 267 MG + PYRAZINAMIDE - 500 MG

TUBERCULOSTATIC

AKURIT4

Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG +ETHAMBUTOL - 275 MG + PYRAZINAMIDE - 400 MG

TUBERCULOSTATIC

AKURIT3

Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG + ETHAMBUTOL -275 MG

TUBERCULOSTATIC

AKURITEach tablet contains RIFAMPICIN - 150 MG + ISONIAZID -75 MG

TUBERCULOSTATIC

AKURIT Z KID

Each tablet contains RIFAMPICIN - 60 MG + ISONIAZID -30 MG + PYRAZINAMIDE -150 MG

TUBERCULOSTATIC

AKURIT KIDEach tablet contains RIFAMPICIN - 60 MG + ISONIAZID - 30 MG

TUBERCULOSTATIC

COMBUTOL 200

Each tablet contains ETHAMBUTOL - 200 MG

TUBERCULOSTATIC

COMBUTOL 400


TUBERCULOSTATIC

COMBUTOL 600


TUBERCULOSTATIC

COMBUTOL 800


TUBERCULOSTATIC

COMBUTOL 1000


TUBERCULOSTATIC

COMBUNEXEach tablet conatins ETHAMBUTOL - 800 MG + ISONIAZID - 300 MG

TUBERCULOSTATIC

PYZINAKIDEach tablet contains PYRAZINAMIDE - 300 MG

TUBERCULOSTATIC

PYZINA 500Each tablet contains PYRAZINAMIDE - 500 MG

TUBERCULOSTATIC


TUBERCULOSTATIC


TUBERCULOSTATIC

R-CIN 150 MGEach capsule contains RIFAMPICIN - 150 MG

TUBERCULOSTATIC


TUBERCULOSTATIC


TUBERCULOSTATIC


TUBERCULOSTATIC

R-CIN SYRUPEach 5ml containsRIFAMPICIN - 100 MG

TUBERCULOSTATIC

R-CINEX 450 MG

Eah tablet contains RIFAMPICIN - 450 MG+ ISONIAZID - 300 MG

TUBERCULOSTATIC

R-CINEX 600 MG

Each tablet contains RIFAMPICIN - 600 MG +ISONIAZID - 300 MG

TUBERCULOSTATIC

R-CINEX KIDEah tablet containsRIFAMPICIN - 100 MG + ISONIAZID - 100 MG

TUBERCULOSTATIC

R-CINEX ZEah tablet contains RIFAMPICIN - 225 MG + ISONIAZID - 150 MG + PYRAZINAMIDE - 750MG

TUBERCULOSTATIC

RCINEX EEah tablet contains RIFAMPICIN - 450+ ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG

TUBERCULOSTATIC

RCINEX EZ Eah tablet contains RIFAMPICIN TUBERCULOSTATIC

- 225 MG + ISONIAZID - 150 MG +ETHAMBUTOL - 400 MG + PYRAZINAMIDE - 750 MG

RCINEX DTEah tablet contains RIFAMPICIN - 100 MG + ISONIAZID - 50 MG

TUBERCULOSTATIC

RCINEX Z KIDEah tablet contains RIFAMPICIN - 100 MG + ISONIAZID - 50 MG + PYRAZINAMIDE - 300 MG

TUBERCULOSTATIC

RINIZIDE FORTE DT

Eah tablet contains RIFAMPICIN -150 MG + ISONIAZID -100 MG + PYRAZINAMIDE -500 MG

TUBERCULOSTATIC

ETHIDE TABLETS

Eah tablet contains ETHIONAMIDE - 250 MG

TUBERCULOSTATIC

PETHIDEEah tablet contains PROTHIONAMIDE - 250 MG

TUBERCULOSTATIC

Q-PAS PARA-AMINOSALICYLIC ACID TUBERCULOSTATIC

CYCLORIN 250 MG

Each capsule contains CYCLOSERINE - 250 MG

TUBERCULOSTATIC

EFFICIN 500MG

Each vial contains KANAMYCIN - 500 MG

TUBERCULOSTATIC

EFFICIN 750MG


TUBERCULOSTATIC

EFFICIN 1000MG


TUBERCULOSTATIC

RIBUTINEah tablet contains RIFABUTIN - 150 MG

HIV-TUBERCULOSTATIC

BENZEach pearl contains BENZONATATE - 100 MG

COUGH SUPRESSANT

E-CEF 125 MG

Each vial contains CEFTRIAXONE - 125 MG

ANTI-INFECTIVES/ ANTI-BIOTICS

E-CEF 250 MG



E-CEF 500 MG



E-CEF 1000 MG



ECEF ODEach vial contains CEPHALEXIN - 250 MG


ECEF S 1.5Each vial contains CEFTRIAXONE+SULBACTAM 1500 MG


ECEF S 750MG

Each vial contains CEFTRIAXONE+SULBACTAM 750 MG


ECEF S 375 MG

Each vial contains CEFTRIAXONE+SULBACTAM 375 MG


GCIN Eah tablet contains GEMIFLOXACIN - 320 MG


LCIN 750Eah tablet contains LEVOFLOXACIN - 750 MG


LCIN OZEah tablet contains LEVOFLOXACIN - 250 MG + ORNIDAZOLE - 500 MG


LCIN IVEach vial contains LEVOFLOXACIN - 500MG/100ML


RTIST 300MGEach capsule contains CEFDINIR - 300 MG


RTIST SUSPEach 5ml contains CEFDINIR - 125MG/5ML


NECTERA POWDER

Each 3gm powder contains 500mg COLOSTRUM (28%IgG) - 90gm TIN

NUTRACEUTICAL

DEFNALONE 1MG

Each tablet conatins DEFLAZACORT -1 MG

GLUCOCORTICOID / STERIOD

DEFNALONE 6MG

Each tablet contains DEFLAZACORT - 6 MG


DEFNALONE 24MG



DEFNALONE 30MG



LUPIGEST 100

NATURAL PROGESTERONE - 100 MG

HormonesLUPIGEST 200

NATURAL PROGESTERONE - 200 MG

YAMINIDROSPIRENONE - 3 MG +ETHINYLESTRADIOL - 0.03 MG Hormones

MEFNIL MIFEPRISTONE - 200 MG

MISONIL -200 MCG

MISOPROSTOL - 200 MCG

HormonesMISONIL -25 MCG

MISOPROSTOL - 25 MCG

FASTRACE PREGNANCY KIT Pregnancy Detection

OVIPHENE-25 CLOMIFENE CITRATE - 25 MGHormones

OVIPHENE-50 CLOMIFENE CITRATE - 50 MG

LUPI-HMG 75IU

HUMAN MENOPAUSAL GONADOTROPIN INJ. 75 I.U.

HormonesLUPI-HMG 150IU

HUMAN MENOPAUSAL GONADOTROPIN INJ. 150 I.U.

LUPI-FSH 75IU

FOLLICLE STIMULATING HORMONE INJ. 75 I.U.

HormonesLUPI-FSH 150IU

FOLLICLE STIMULATING HORMONE INJ. 150 I.U.

LUPI-HCG 2000

HUMAN CHORIONIC GONADOTROPIN INJ. 2000 I.U.

HormonesLUPI-HCG 5000

HUMAN CHORIONIC GONADOTROPIN INJ. 5000 I.U.

LUPI-HCG 10000

HUMAN CHORIONIC GONADOTROPIN INJ.10000 I.U.

MindVision

Brand Name

Molecule Therapy Segment

Stalopam Escitalopram 5mg Antidepressant

Escitalopram 10mg Antidepressant

Escitalopram 20mg Antidepressant

Stalopam PlusEscitalopram 10mg + Clonazepam 0.5mg

Antidepressant

Citistar Citicoline 500mg Nootropic

Citicoline (250mg/ml) Nootropic

Citicoline 500mg (250mg/ml) Nootropic

Citicoline 1000 mg Sustained Release tablets

Nootropic

Epilive Levetiracetam 250mg Tablets Antiepileptics

Levetiracetam 500mg Tablets Antiepileptics

Levetiracetam 750mg Tablets Antiepileptics

Lovax Oxcarbazepine 150mg Antiepileptics

Oxcarbazepine 300mg Antiepileptics


Lovax ODOxcarbazepine 300mg Extended Release

Antiepileptics


Extended Release

Dayo OD Divalproex 250mg Antiepileptics

Divalproex 500mg Antiepileptics

Divalproex 750mg Antiepileptics

Pregadoc Pregabaline 75mg Agent for neurpathic pain

Pregabaline 150mg Agent for neurpathic pain

Pregadoc MPregabalin 75mg + Mecobalamin 750mcg Capsules

Agent for Neuropathic Pain

Pregabalin 150mg + Mecobalamin 750mcg Capsules

Agent for Neuropathic Pain

Amigold Amisulpride 50mg Antipsychotic

Amisulpride 100mg Antipsychotic

Amisulpride 200mg Antipsychotic

Jolyon - MD Olanzepine 5mg Antipsychotic

Olanzepine 7.5mg Antipsychotic

Olanzepine 10mg Antipsychotic

Olanzepine 15mg Antipsychotic

Arzu Aripiprazole 15mg Antipsychotic

Aripiprazole 10mg Antipsychotic

Aripiprazole 30mg Antipsychotic

Placidin Quetiapine 100mg Antipsychotic

Quetiapine 200mg Antipsychotic

Quetiapine 25mg Antipsychotic

PlaciDox Diazepam 10mg Tranquilizers

Diazepam 2mg Tranquilizers

Diazepam 5mg Tranquilizers

DULOT Duloxetine 20mg Antidepressant

Duloxetine 30mg Antidepressant

Anxicalm Alprazolam 0.25mg Tranquilizers

Alprazolam 0.5mg Tranquilizers

Goodnoct XR Zolpidem 6.25mg Extended Release Tablets

Hypnotic

Zolpidem 12.5mg Extended Release Tablets

Hypnotic

Tolifast Tolperisone 150mg Tablets Muscle Relaxant

Movexol Pramipexole 0.25mg Tablets Drug for Parkinson's Disease

Pramipexole 0.5mg Tablets Drug for Parkinson's Disease

Pramipexole 1mg Tablets Drug for Parkinson's Disease

Fibril Ispaghula husk Laxatives

Fibril SF Ispaghula husk Laxatives

Ribavin 200 mg Ribavirin 200mg Hepatitis C

Ribavirin 50mg Hepatitis C

Alzidoc Donepezil 5mg Tablets Drug for Alzheimer's Disease

Donepezil 10 mg Tablets Drug for Alzheimer's Disease

Restfull Flupentixol 0.5mg + Melitracen 10mg Tablets

Anxiolytic

Edastar Edaravone injection 1.5 mg/mL(20 mL)

Other CNS drugs

PinnacleFor more details on the below given information, kindly visit www.epinnacleworld.com


TONACT 5 Atorvastatin Cholesterol Reducer





TONACT PLUS Atorvastatin + Niacin Cholesterol Reducer

TONACT FORTE Atorvastatin + Niacin Cholesterol Reducer

TONACT 10MG EZ Atorvastatin +Ezetimibe Cholesterol Reducer

TONACT 20mg EZ Atorvastatin +Ezetimibe Cholesterol Reducer

TONACT TG Atorvastatin + Fenofibrate Cholesterol Reducer

TONACT 10 MP Atorvastatin Cholesterol Reducer

TRITONACTAtorvastatin + Fenofibrate + Ezetimibe

Cholesterol Reducer

TONACT-TM Atorvastatin + TelmisartanCholesterol Reducer + Anti-Hypertensive

http://www.epinnacleworld.com/

RAMISTAR 1.25 Ramipril Anti-Hypertensive

RAMISTAR 2.5MG Ramipril Anti-Hypertensive

RAMISTAR 5MG Ramipril Anti-Hypertensive

RAMISTAR 10MG Ramipril Anti-Hypertensive

RAMISTAR A 2.5 Ramipril + Amlodipine Anti-Hypertensive

RAMISTAR H 2.5 Ramipril +Hctz Anti-Hypertensive

RAMISTAR H 5 Ramipril +Hctz Anti-Hypertensive

RETORLIX 5 Torsemide Diuretic




RETORLIX injection

Torsemide Diuretic

RETORLIX SPTorsemide + Spironolactone

Diuretic

VALENT 40 Valsartan Anti-Hypertensive

VALENT 80mg Valsartan Anti-Hypertensive

VALENT H Valsartan + Hctz Anti-Hypertensive

VALENT 160 Valsartan Anti-Hypertensive

VALENT R Valsartan +Ramipril Anti-Hypertensive

PINOM 10 Olmesartan Anti-Hypertensive

PINOM 20 Olmesartan Anti-Hypertensive

PINOM 40 MG Olmesartan Anti-Hypertensive

PINOM H Olmesartan + Hctz Anti-Hypertensive

PINOM A 20 MG Olmesartan + Amlodipine Anti-Hypertensive

CLOPITAB 75mg Clopidogrel Antiplatelet

CLOPITAB 150 Clopidogrel Antiplatelet

CLOPITAB A 75 Clopidogrel + Aspirin Antiplatelet

CLOPITAB A 150 Clopidogrel + Aspirin Antiplatelet

CILODOC 50 Cilostazol Antiplatelet

CILODOC 100 Cilostazol Antiplatelet

FAXIMAB 10MG/5 ML VIAL

Abciximabinj Antiplatelet

LUPENOX 20MG Enoxaparin Anticoagulant



PLANEP Eplerenone Diuretic

ISONORM 10 IsosordibeMononitrate Antianginal

ISONORM 20 IsosordibeMononitrate Antianginal

ISONORM 30 SR IsosordibeMononitrate Antianginal

IVABRAD 5MG Ivabradine Antianginal

IVABRAD 7.5MG Ivabradine Antianginal

DOFUSE Injection Dobutamine Positive Ionotropes

LUPIDIP 2.5/5/10 mg

Amlodipine Anti-Hypertensive

LUPIBOSE 62.5/125 mg

Bosentan Pulmonary Anti-Hypertensive

HARTYResveratrol + Grape seed extract

Nutritional Supplement

Pinnacle CVN (CARDIOVASCULAR NEPHROLOGY)


ATENOVA 25 MG

Atenolol Anti-Hypertensive

ATENOVA 50 MG


ATENOVA 100 MG


EZEDOC Ezetimibe Cholesterol Reducer

FRUSELACFrusemide + Spironolactone

Diuretic

FRUSELAC DS Frusemide + Diuretic

Spironolactone

ISONORM 10 IsosordibeMononitrate Anti-Anginal

ISONORM 20 IsosordibeMononitrate Anti-Anginal

ISONORM 30 SR IsosordibeMononitrate Anti-Anginal

LIPRIL 2.5mg Lisinopril Anti-Hypertensive

LIPRIL 5mg Lisinopril Anti-Hypertensive

LIPRIL 10mg Lisinopril Anti-Hypertensive

LIPRIL AM Lisinopril + Amlodipine Anti-Hypertensive

LIPRIL HLisinorpil + Hydrochlorothiazide

Anti-Hypertensive

NEBISTAR 2.5mg

Nebivolol Anti-Hypertensive

NEBISTAR 5mg Nebivolol Anti-Hypertensive

NEBISTAR SANebivilol + s-amlodipine

Anti-Hypertensive

NEBISTAR HNebivilol + Hydrochlorothiazide

Anti-Hypertensive

STARPRESS XL 100

Metoprolol Anti-Hypertensive

STARPRESS XL 25


STARPRESS XL 50


STARPRESS H 25 XL

Metoprolol + Hydrochlorothiazide

Anti-Hypertensive

STARPRESS H 50 XL

Metoprolol + Hydrochlorothiazide

Anti-Hypertensive

STARPRESS AM Metoprolol + Anti-Hypertensive

XL 30 Amlodipine

STARPRESS AM XL

Metoprolol + Amlodipine

Anti-Hypertensive

STARPRESS MN XL 30

Metolprolol + Isosorbidemononitrate

Anti-Hypertensive+Anti-Anginal

STARPRESS MN XL 60

Metolprolol + Isosorbidemononitrate

Anti-Hypertensive+Anti-Anginal

STARPRESS R XL 25

Metoprolol + Ramipril Anti-Hypertensive

STARPRESS R XL 50

Metoprolol + Ramipril Anti-Hypertensive

RANCAD Ranolazine Anti-Anginal

NOVASTAT 5MG Rosuvastatin Cholesterol Reducer

NOVASTAT 10MG

Rosuvastatin Cholesterol Reducer

NOVASTAT 20MG

Rosuvastatin Cholesterol Reducer

FLETA BOLUS INJ

Eptifibatide Antiplatelet

FLETA INFUSION

Eptifibatide Antiplatelet

TIROFUSE Tirofiban Antiplatelet

LUPIFLO 7.5 LRecombinant Streptokinase

Fibrinolytic

LUPIFLO 15 LRecombinant Streptokinase

Fibrinolytic

SENACEPT Cinacalcet HCL Calcimimetic

Endeavour


CALUFT CAPS CALCIUM CARBONATE + CALCITRIOL + ZINC + MAGNESIUM + BORON

ANTI-OSTEOPOROSIS

CALUFT-G CALCIUM CITRATE MALEATE + VIT.D3 + ZINC + MANGANESE + MAGNESIUM + COPPER

CALCIUM PREPARATION

CEFAXONE 1000 Mg

CEFTRIAXONE IM/IVANTI INFECTIVE INJECTABLE

CEFAXONE 125 Mg


CEFAXONE 250 Mg


CEFAXONE 500 Mg


CEFFOREN CEFDITORENAnti-bacterial (CEPHALOSPORIN ORAL)

CO-Q-DENT CO-Q-10HERBAL TOOTHPASTE

CO-Q-DENT CO-Q-10HERBAL TOOTHPASTE

CZ-3 COLDPHENYLPROPANOLAMINE 25MG + CETIRIZINE 5MG + PARACETAMOL 500MG

COLD PREPARATION

CZ-3 SYRUP CETRIZINE ANTI-HISTAMINE

CZ-3 TABLET CETRIZINE ANTI-HISTAMINE

CZ-COLD CETRIZINE 5MG + PSEUDOEPHEDRINE 30MG/5ML

COLD PREPARATION

CZ-EX AMBROXOL 15MG + R-SALBUTAMOL 1MG + GUAIPHENESIN 50 MG + MENTHOL 0.5MG

COUGH PREPARATION

CZ-TUS DEXTROMETHORPHAN + CETRIZINE + PSEUDOEPHEDRINE + MENTHOL

COUGH PREPARATION

DOXCEF 100 CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)

DOXCEF 100 DRY SYRUP

CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)

DOXCEF 200 CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)

DOXCEF 50 DRY SYRUP


DOXCEF 50 DT CEFPODOXIMEAnti-bacterial (CEPHALOSPORIN ORAL)

DOXCEFF DT 100 MG


EUBIOZ CAP PREBIOTIC PROBIOTIC COMBINATION Gastro-intestinal

EUBIOZ SACHET

PREBIOTIC PROBIOTIC COMBINATION Gastro-intestinal

HEPP FORTE SYRUP

- HAEMATINIC

LUPIN TAZOX 250 MG

CEFTRIAXONE + TAZOBACTAMANTI INFECTIVE INJECTABLE

LUPIN TAZOX 1 GM

CEFTRIAXONE + TAZOBACTAMANTI INFECTIVE INJECTABLE

LUPINEM 500 MG IMIPENEM + CILASTATINANTI INFECTIVE INJECTABLE

MAGNOVA 1G CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE

MAGNOVA 250 MG

CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE

MAGNOVA 5G CEFEPIME+TAZOBACTAMANTI INFECTIVE INJECTABLE

NIZONIDE NITAZOXANIDE Anti-diarrhoeal

NIZONIDE DT TABLET

NITAZOXANIDE Anti-diarrhoeal

NIZONIDE SUSP NITAZOXANIDE Anti-diarrhoeal

NIZONIDE-O NITAZOXANIDE + OFLOXACIN Anti-diarrhoeal

NIZONIDE-O SUSP

NITAZOXANIDE + OFLOXACIN Anti-diarrhoeal

Novapime 1000 mg

CEFEPIME CEPHALOSPORIN INJ

NOVAPIME 250 MG INJ


Novapime 500 mg


ODOXIL 125 DT CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL 250 DT TABLETS

CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL 250 PREMIX


ODOXIL 500 Mg CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL DS CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL OD CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL PREMIX CEFADROXILAnti-bacterial (CEPHALOSPORIN ORAL)

ODOXIL SUSPENSION


OPTINEURON INJ

VITAMIN B COMPLEX NEUROTROPIC

OPTINEURON TABS

VITAMIN B COMPLEX NEUROTROPIC

PERCIN PRULIFLOXACIN 600MGORAL ANTI-INFECTIVE

RABLET 10 MG RABEPRAZOLE Anti-peptic Ulcerant




RABLET D caps RABEPRAZOLE + DOMPERIDONE Gastro-intestinal

RABLET I.V. SALES (1

RABEPRAZOLE IV Anti-peptic Ulcerant

RABLET IT RABEPRAZOLE+ITOPRIDE Gastro-intestinal

RCIFAX RIFAXIMINGI Anti-bacterial (RIFAMPICIN DERIVATIVE)

RCLONAC TABLET 10 X

DICLOFENAC SR+ RABEPRAZOLE NSAID + APU

RESNER INJ MECOBALAMINE NEUROTROPIC

RESNER SOFT CAPSULES

MECOBALAMINE NEUROTROPIC

SIGNOFLAM -P TAB

ACECLOFENAC NSAIDS

SIGNOFLAM TABLET

ACECLOFENAC NSAIDS

SOFTOVAC ISABGOL COMBINATION LAXATIVE

SOFTOVAC SF ISABGOL COMBINATION LAXATIVE

TOPCERIN DIACEREINOTHER PLAIN ANTI ARTHRITIC

ULYSES 150 MG URSODESOXYCHOLIC ACIDHEPATO-PROTECTIVE

ULYSES 300 MG URSODESOXYCHOLIC ACIDHEPATO-PROTECTIVE

VIDA-25 LOSARTAN ANTI HYPERTENSIVE

VIDA-50 LOSARTAN ANTI HYPERTENSIVE

VIDA-H LOSARTAN+HYDROCHLOROTHIAZIDE ANTI HYPERTENSIVE

Lupin Diabetes Care

Brand Name Molecule Therapy segment

Gluconorm SRMetformin 500 mg extended release

Diabetes Management

Gluconorm SR 1 g

Metformin 1 gm extended release

Diabetes Management

Gluconorm G1Metformin 500 mg ER + Glimepiride 1 mg

Diabetes Management

Gluconorm G2Metformin 500 mg ER + Glimepiride 2 mg

Diabetes Management

Gluconorm P15Metformin 500 mg ER + Pioglitazone 15 mg

Diabetes Management

Gluconorm P30Metformin 500 mg ER + Pioglitazone 30mg

Diabetes Management

Gluconorm PG-1

Metformin 500 mg ER + Pioglitazone 15 mg + Glimepiride 1 mg

Diabetes Management

Gluconorm PG-2

Metformin 500 mg ER + Pioglitazone 15 mg + Glimepiride 2 mg

Diabetes Management

Gluconorm G1 Forte

Metformin 1 gm ER + Glimepiride 1mg

Diabetes Management

Gluconorm G2-1 Forte

Metformin 1 gm ER + Glimepiride 2 mg

Diabetes Management

Glutide CR 30MG

Gliclazide Controlled Release 30 mg

Diabetes Management

Glutide CR 60MG

Gliclazide Controlled Release 60 mg

Diabetes Management

Glador 1 Glimepiride 1 mg Diabetes Management




Lipril 2.5 Lisinopril 2.5 mg Diabetic Hypertension

Lipril 5 Lisinopril 5 mg Diabetic Hypertension

Lipril 10 Lisinopril 10 mg Diabetic Hypertension

Lipril AM Lisinopril 5 mg + Amlodipine 5 mg Diabetic Hypertension

Lipril HLisinopril 5 mg + Hydrochlorothiazide 12.5 mg

Diabetic Hypertension

Matilda Plus Mecobalamin 750 mcg + ALA 100 mg+ Pyridoxine 3mg + Folic aci

Diabetic Neuropathy Management

Matilda Forte Mecobalamin 1500 mcg + ALA 200 mg + Folic acid 1.5 mg + Pyri


Matilda AFMecobalamin 750 mcg + ALA 100mg + GLA 60 mg + Benfothiamin


Matilda ERMecobalamin 1500 mcg + Pyridoxine 20mg + Folic acid 5mg


Matilda Inj 1x1ml

Mecobalamin 500 mcg I.M./I.V. Diabetic Neuropathy Management

Misobit 25 Miglitol 25 mg Diabetes Management

Misobit 50 Miglitol 50 mg Diabetes Management

Misobit MD 25 Miglitol Mouth Dissolving 25 mg Diabetes Management

Misobit MD 50 Miglitol Mouth Dissolving 50 mg Diabetes Management

Path 15mg Pioglitazone 15 mg Diabetes Management

Path 30 mg Pioglitazone 30 mg Diabetes Management

Path G1Pioglitazone 15 mg + Glimepiride 1 mg

Diabetes Management

Path G2Pioglitazone 15 mg + Glimepiride 2 mg

Diabetes Management

Retorlix 5 Torsemide 5 mg Diabetic Hypertension




Retorlixinj Torsemide Injection 10mg/ml Diabetic Hypertension

Retorlix SP 5Torsemide 5 mg + Spironolactone 50 mg


Retorlix SP 10Torsemide 10 mg + Spironolactone 50 mg


Starstat 5 Simvastatin 5 mg Diabetic Dyslipidemia




Starstat EZ 10 Simvastatin 10 mg + Ezetimibe Diabetic Dyslipidemia

Starstat EZ 20 Simvastatin 20 mg+ Ezetimibe Diabetic Dyslipidemia

Telista 20 Telmisartan 20 mg Diabetic Hypertension



Telista HTelmisartan 40 mg + Hydrochlorothiazide 12.5 mg


Telista RM 2.5Telmisartan 40 mg + Ramipril 5 mg


Telista - RM 5Telmisartan 40 mg + Ramipril 2.5 mg


Telista - AMTelmisartan 40 mg + Amlodipine 5mg


GABASTAR 300 Gabapentin 300 mg Diabetic Neuropathy Management

GABASTAR SR 600

Gabapentin sustained release 600 mg


GABASTAR MGabapentin 300 mg + Mecobalamin 500 mcg


GABASTAR MAX

Gabapentin 300 mg + Mecobalamin 500 mcg + ALA 100 mg


PREGASTAR 75 Pregabalin 75 mg Diabetic Neuropathy Management

PREGASTAR Pregabalin 150 mg Diabetic Neuropathy Management

150

PREGASTAR M 75

Pregabalin 75 mg + Mecobalamin 750 mcg


PREGASTAR M 150

Pregabalin 150 mg + Mecobalamin 750 mcg


DUMORE 20 Duloxetine 20 mg Diabetic Neuropathy Management



DUMORE M 20Duloxetine 20 mg + Mecobalamin 750 mcg






RIBAFIT Rimonabant 20 mg Diabetic Dyslipidemia

Vobit 0.2mg Voglibose 0.2 mg Diabetes Management

Vobit 0.3mg Voglibose 0.3 mg Diabetes Management

LUPSULIN N 40 Recombinant Human Insulin NPH Diabetes Management

LUPSULIN R 40Recombinant Human Insulin Regular

Diabetes Management

LUPSULIN M 30/70

Recombinant Human Insulin 30% Regular & 70% NPH

Diabetes Management

LUPSULIN M 50/50

Recombinant Human Insulin 50% Regular & 50% NPH

Diabetes Management

NOVASTAT 5 Rosuvastatin 5 mg Diabetic Dyslipidemia



LupinRespira


BUDAMATE 100 TRANSCAPS(DPI)

Formoterol 6 mcg & Budesonide 100 mcg

ICS+LABA

BUDAMATE 200 TRANSCAPS(DPI)


ICS+LABA

BUDAMATE 400 INHALER(MDI)


ICS+LABA

BUDAMATE 100 INHALER(MDI)BOX


ICS+LABA

BUDAMATE 400 TRANSCAPS (DPI)


ICS+LABA

BUDAMATE 200 INHALER(MDI)BOX


ICS+LABA

BUDATE 100 DPI Budesonide 100 mcg ICS

BUDATE 100 MDI Budesonide 100 mcg ICS


BUDATE 200 MDI Budesonide 200 mcg ICS


BUDATE 4X5X2ML Budesonide.5mg per 2 ML ICS

BUDATE FORTE 4X5X2ML

Budesonide 1mg per 2ml ICS

BUDATE 3X7X2ML Budesonide.5mg per 2 ML ICS

ESIFLO 125 INHALER(MDI)BOX

Salmeterol 25 mcg & Fluticasone 125 mcg

ICS+LABA

ESIFLO 250 INHALER(MDI) BOX


ICS+LABA

ESIFLO500 TRANSCAPS


ICS+LABA

ESIFLOR 100 Salmeterol 50 mcg & Fluticasone ICS+LABA

TRANSCAPS (DPI) 100 mcg

ESIFLOR 250 TRANSCAPS (DPI)


ICS+LABA

FLUTIFLOFLUTICASONE 50 MCG EACH SPRAY

INCS

IPNEB 15ML Ipratropium 250 mcg/per ml ANTICHOLINERGIC

MOMEFLOmometasone 50 mcg in each spray

INCS

SALBAIR (MDI) Levo-Salbutamol 50 mcg BRONCHODILATOR

SALBAIR TRANSCAPS(DPI)

Levo-Salbutamol 100 mcg BRONCHODILATOR

SALBAIR 1 TRANSCAPS(DPI)

Levosalbutamol 100mcg+ipratropium 40 mcg

BRONCHODILATOR + ANTOCHOLINERGIC

SALBAIR 1 TRANSCAPS(DPI)

Levosalbutamol 100mcg+ipratropium 40 mcg

BRONCHODILATOR + ANTOCHOLINERGIC

SALBAIR 1 TRANSPULE

salbutamol 2,5mg+ipratropium500mcg for 2.5ml

BRONCHODILATOR

SALBAIR 15ML salbutamol 5mg/ml BRONCHODILATOR

SALBAIR B (MDI)BOX

levosalbutamol 50mcg+beclomethasone 50mcg

ICS+BRONCHODILATOR

SALBAIR B FORTE TRANSCAPS (DPI)

Levosalbutamol 100mcg+beclomethasone200mcg

ICS+BRONCHODILATOR

SALBAIR B TRANSCAPS (DPI)

levosalbutamol 100+ beclomethasone 100mcg

ICS+BRONCHODILATOR

SALBAIR I (MDI) BOX

levosalbutamol 50 mcg+ipratropium 20 mcg

ICS+ ANTICHOLINERGIC

SALBAIR TRANSCAPS (DPI)

levosalbutamol 50 mcg BRONCHODILATOR

SALBAIR TRANSPULES

salbutamol 2.5mg per 2.5 ml BRONCHODILATOR

TIATE DPI Tiotropium 18 mcg ANTICHOLINERGIC

TIATE MDI Tiotropium 9 mcg ANTICHOLINERGIC

TIOMATE DPITiotropium 18 mcg &Formoterol 12 mcg

ANTICHOLINERGIC + LABA

TIOMATE MDITiotropium 9 mcg &Formoterol 6 mcg

ANTICHOLINERGIC + LABA

AZEFLOAzelastine 140 mcg + 50 mcg fluticasone each spray

ANTIHISTAMINE+ INCS

LUPIHALER Advanced Mono Dose Device DRUG DELIVERY SYSTEM

TELEKAST 4MGMontelukast Sodium Chewable Tablets 4 mg

ANTILEUKOTRIENE

TELEKAST 5MGMontelukast Sodium Chewable Tablets 5 mg

ANTILEUKOTRIENE

TELEKAST 10Montelukast Sodium Tablets 10 mg

ANTILEUKOTRIENE

TELEKAST PLUSMontelukast 10 mg &Bambuterol 10 mg

ANTILEUKOTRIENE + BRONCHODILATOR

TELEKASTLMontelukast 10 mg &Levocetirize 5 mg

ANTILEUKOTRIENE + ANTIHISTAMINE

LUDO 120 MDI Dose Counter DOSE COUNTER

STERIO 4Methyl Prednisolone Tablets 4 mg

ORAL STEROID


ORAL STEROID


ORAL STEROID

DOXIFLO 400MG Doxofylline tablets 400 mg BRONCHODILATOR

FORMOFLO 125 MDI

Formoterol 6 mcg & Fluticasone 125 mcg

ICS+LABA

FORMOFLO 250 MDI

Formoterol 6 mcg & Fluticasone 250 mcg

ICS+LABA

FORMOFLO 100Formoterol 6 mcg & Fluticasone 100 mcg

ICS+LABA

FORMOFLO 250 Formoterol 6 mcg & Fluticasone 250 mcg

ICS+LABA

DUOMATE TRANSCAPS

Formoterol 6 mcg &Beclomathasone 200 mcg

ICS+LABA

DUOMATE FORTEFormoterol 6 mcg &Beclomathasone 400 mcg

ICS+LABA

APTIVATE 9 natural ingredients APPITIZER

LCIN 250MG Levofloxacin 250 mg tablets ANTIBIOTIC

LCIN 500MG Levofloxacin 500 mg tablets ANTIBIOTIC

LCIN A - -

STARCET 5MG Levocetirizine 5 mg tablets ANTIHISTAMINE

STARCET Alevocetirizine 5 mg+ambroxol 75 tablets

ANTIHISTAMINE + MUCOLYTIC

STARCET COLDLevocetrizine 2.5mg+paracetamol 500mg+psedoephradine 60 mg

ANTIHISTAMINE + MUCOLYTIC+ANALGESIC

LCF COUGH FORMULA

Levosalbutamol 1mg+guaiphenesin 50 mg+ambroxol 15mg/5ml

COUGH FORMULA

LCF KIDLevosalbutamol .5mg+guaiphenesin 50 mg+ambroxol 15mg/5ml

COUGH FORMULA

INCS INTRANASAL CORTICOSTEROID -

ICS INHALEDCORTICOSTEROID -

LABALONG ACTING BRONCHODILATOR

-

MARKET SHARE OF LUPIN PHRMA

Lupin Q4 & FY 2008-09 Results - Consistent Performance & Solid Growth

Q4 2008-09 Consolidated Net Profits up 64.2% at Rs. 1574 million

May 13, 2009, Mumbai, India

Leading transnational pharmaceutical major, Lupin Limited, reported an outstanding performance for the fourth quarter and financial year ended March 31st, 2009. These audited results were taken on record by the Board of Directors at a meeting held in Mumbai today.

Key Highlights - Consolidated FY 08-09

Net sales grew at 39.5% to Rs. 37759 million from Rs. 27064 million

last year Net profit grew at 50.2% to Rs. 5015 million compared

to Rs. 3338 mn in previous year (excluding IP income) EBITDA margin increased to 19.7% Exports up by 63.2% at Rs. 24701 mn Advanced markets sales (including Japan and ANZ)

increased to 92% over last year and contributed 50% of the Net Sales for the year as against 36% in the previous year.

Advanced Markets sales to US and EU grew at 70% to Rs.14310 million including API

One of the fastest growing generic players in the US by prescriptions and the 9th largest in terms of total prescription base

A basket of 22 products in the US with 8 market leaders

Domestic Formulations Business grew at 24.6%% to Rs. 10,575 million.

Lupin’s Japanese subsidiary, Kyowa contributed 12% of the overall revenues - Rs. 4424 million

28 ANDAs, 15 DMFs, 18 MAAs,6 EDMFs,3 COS, & 1 AU DMF were filed during FY 08-09.

Four Major Acquisitions across Germany, Australia, South Africa and the Philippines

Dividend Announcement of 125 %

Key Highlights Q4 FY 08-09

Net sales for Q4 FY 08-09 grew at 39% to Rs.10434 million.

Advanced markets sales (U.S, EU & Japan) increased to 86 % at Rs 5681 million over Q4 FY 07-08

Net profit for Q4 FY 08-09 grew at 64.2% to Rs.1574 million compared to Rs. 959 million in Q4 FY 07-08

Commenting on Lupin’s performance, Dr. Kamal K Sharma, Managing Director, Lupin Limited, said, “Lupin’s stellar performance reflects the strong business philosophy guiding us. Lupin has had a very strong year driven by growth and consistent performance across all business segments and markets: a strong business performance in the US, solid domestic growth & increased activity in all key markets. Lupin’s acquisitions have not only consolidated our existing presence in these markets but also leaves us strategically poised to further strengthening our position in the global generics and branded generics market. It has indeed been a year of many achievements and robust growth, and we are now strategically poised to not only address market needs but also maintain momentum and direction.”

Financials:

Advanced markets – US & Europe

Lupin continued its growth momentum in the US and Europe a healthy contribution of 36% to our total revenues at Rs. 13634 million. (Formulations)

USA:

Lupin Pharmaceuticals Inc., the company’s US subsidiary, reported a stellar performance recording sales of Rs. 12563 million reflecting a growth of 74.4% as compared to Rs. 7205 million in FY 07-08. Lupin’s Generic and Branded business recorded exponential growth during the financial year.

More importantly, FY 08-09 saw Lupin increasing its product portfolio in the branded generics segment through the launch of AeroChamber Plus®. LPI forged a Strategic Alliance with Forest Laboratories, Inc. for marketing and promoting AeroChamber Plus® thereby extending Lupin’s presence in the respiratory segment and our franchise with Pediatricians which would also additionally open up new offices for Suprax. The brand business contributed 27% to the overall business at USD 74 mn

The company further expanded and consolidated on its generic product portfolio with the launches of Ramipril caps, Divalproex DR tabs, Cefadroxil suspension and caps &Levetiracetam tabs. The Company now has a total of 22 products in the market, out of which 8 are market leaders. We are in the top 3 market positions by market share in 17 of these products (IMS Jan 09).

Lupin today is one of the fastest growing generic players in the US based on growth in prescriptions and the 9th largest in terms of total prescription base.

LPI was also recognized by Wal-Mart and awarded its prestigious “Supplier Award of Excellence” for the 2nd Quarter 2008 – which is an acknowledgement of the inroads we have made into the US markets.

During the year, the company demonstrated its capabilities on the Intellectual Property management front by successfully litigating and settling all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough’s "Clarinex"® tablets. As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances. Schering-Plough’s Clarinex® tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have commenced.

Lupin’sLevetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals’ Keppra® tablets, indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy. Keppra tablets had annual sales of approximately $ 1.2 billion (USD) for the twelve months ended September 2008, based on IMS Health sales data.

Europe:

Lupin further strengthened its presence in the European Union by completeing its acquisition of HormosanPharma GmbH (Hormosan), a German generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS).

We also recorded our first strategic win in the German market through Hormosan in the next two quarters – having received information on the results of the AllgemeineOrtskrankenkassen (AOK) Tender, pursuant to § 130a SGB V. Hormosan has been offered to supply Setraline in all 5 regions of Germany covering all AOK-insured persons.

Hormosan has a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector.

Lupin also made strategic inroads into the French market by launching CefpodoximeProxetil suspension in Q3. CefpodoximeProxetil has over 60 % market share in France.

AAMLA

Japan:

Kyowa, the Company’s subsidiary in Japan posted robust net sales of Rs. 4424 mn contributing 12% of Lupin’s Revenues having grown at over 21 % YoY

Our products like Amlodipine “Amel” continues to maintain majority market share and Risperidone “Amel”, which was launched last year, continue to exhibit market leadership in unit terms.

South Africa

Lupin clocked in revenues of Rs 919 million after having acquired an equity stake in Pharma Dynamics (PD) in South Africa in September 08. Pharma Dynamics is one of the fastest growing generic companies in South Africa growing at around 30 % for FY 08-09 with a clear leadership in the cardiovascular segment.

PD is ranked number 6 amongst generic companies in South Africa. The South African Generics Market is currently valued at close to 800 Million USD and growing rapidly

Phillipines

In March 2009 the Company acquired a majority stake in MulticarePharmaceuticals Phillipines, Inc. (MC) in Phillipines. MC is a premium branded generics company with a strong position in women’s health and child care segment.

ANZ

The Company continued its focus on this important market with aggressive filings in Australia, taking the cumulative MAA filings to 24 till date of which 18 have been approved.

Emerging Markets

India

Domestic Formulations forms a very important part of Lupin’s overall growth. In the current financial year, it contributed about 28% of the net sales at Rs 10,575 million as against Rs. 8,487 million registering a growth of 24.6% over the previous year.

This growth was driven by the good performance in the CVS, Diabetes, CNS, Asthma and Gastro therapy Segments. The

divisions catering to branded segments continued to outpace the industry growing over 27%. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the anti-asthma market riding high on the strengths of its offering in this segment.

Research and Development

Research & Development has always been a strategic and key focus area for Lupin and this year – 2008-09 was no exception with 6% of the sales earmarked for R&D and related spends.

The year 2008-09 was a landmark year with Lupin filing 28 Abbreviated New Drug Application (ANDA) with the USFDA, 11 DMFs, 15 MAAs and two EDMFs during the year.

The cumulative ANDA filings stood at 90 with 34 approvals granted by the USFDA.

Lupin also received the final approval for the Company’s Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA) during the quarter.

Other

The USFDA issued a warning letter for the Cephalosporin facility of the Mandideep plant. The facility was inspected in November, 2008 for a routine GMP inspection. As a result Lupin had received 15 procedural observations. Lupin responded to the observations in December and provided corrective actions for each of the responses.

The warning letter was issued to provide Lupin with an opportunity to submit additional documentation and explanation to a few selected observations where the FDA

felt that the initial responses were inadequate and could be strengthened by further evidence of compliance with enhanced documentation practices.

All products maintain their approved status. Lupin manufacturing will not be disrupted and it will continue to provide quality products to customers without interruption.

Lupin has formulated a strategy to address and resolve the USFDA and is confident of being able to satisfy the USFDA’s observations expeditiously.

Dividend-In view of excellent performance, the Board of Directors recommended a dividend of 125 % i.eRs. 12.50 per equity share of the face value of Rs. 10 each.

COMPANY MANUFACTURING/R&D

Business Development

Lupin was founded to meet the very basic need for effective treatment of tuberculosis. Our success is tied to continually meeting the need for basic products to promote human health. Our company strives to bring important new products to market each year. We expect our products to come from:

In-house product development; Licensing and acquisitions; Marketing alliances.

Lupin is also seeking to be the partner of choice for product development. Our scientists apply know how and expertise to develop NCE’s or to solve difficult formulation challenges.

We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market. We are also open to collaborating to develop innovative products formulated with Lupin’s drug delivery and taste masking

technology. Our API business unit is seeking partners for Lupin developed API's.

Please contact us regarding business or product collaboration opportunities

Phone: 410-576-2000

Facsimile: 410-576-2221

Email: [email protected]

NEW Products

Generics

Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. Since then we have received more than a dozen FDA approvals. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA, reinforcing our ability to submit high quality dossiers and gain on time approvals.

We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive

mailto:[email protected]

prices.

Our integrated manufacturing capability provides a portfolio of the highest quality generic products.

Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 15 or more ANDA’s per year in some of the following areas:

Oral and injectable cephalosporins;Cardiovascular;Controlled release ANDA’s;Paragraph IV’s.

Our oral and injectable cephalosporin facilities, US FDA approved manufacturing sites and the new tablet and capsule facility in Goa, allow us to file and manufacture a wide range of finished products for the US market.

Newsroom

Lupin receives FDA approval for Imipramine Pamoate Capsules

View

Apr 16, 2010

Lupin receives FDA tentative approval for Eszopiclone tablets

View

Mar 20, 2010

Lupin receives FDA approval for Amlodipine/Benazepril capsules

View

Feb 08, 2010

Lupin receives FDA approval for Perindopril Erbumine Tablets

View

Jan 28, 2010

Lupin receives FDA tentative approval for MemantineHCl tablets

View

Jan 19, 2010

Lupin is granted USFDA approval for Levetiracetam Tablets

View

Jan 16, 2009

Lupin Receives “Supplier Award of Excellence” from Wal-Mart

View

Sept 17, 2008

Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets

View

July 29, 2008

Lupin appoints New NCE Research Head. June 26, 2008

View

Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S.

View

June 23, 2008

Lupin receives USFDA approval for Escitalopram Oxalate Tablets

View

June 16, 2008

Lupin launches Ramipril capsules

View

June 10, 2008

Lupin receives USFDA approval for Topiramate Tablets

View

May 29, 2008

Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen

View

July 30, 2007

Lupin receives final approval for Amlodipine Tablets

View

July 12, 2007

Lupin announces Final Approval of Trandolapril Tablets June 13,

View

2007

Lupin Receives US FDA Approval for ZiprasidoneHCl Capsules

View

May 22, 2007

Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension, 250 mg/5 mL, Launches Entire Product Family.

View

May 8, 2007

Lupin Receives US FDA Approval for Novel Formulation of Suprax® Suspension

View

April 12, 2007

Lupin Receives US FDA Approval for Sertraline.

View

February 7, 2007

Products

Specialty

A commitment To Caring For Kids

Lupin Pharmaceuticals, Inc. is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. We are committed to identifying, developing and marketing prescription drugs for children of all ages. Lupin has created a dedicated national sales force to call upon pediatricians.

Lupin Pharmaceuticals, Inc., is very pleased to offer Suprax®, an important anti-infective product in pediatric and other physician practices within the United States. Suprax® is now available in tablets and suspension formulations. Lupin Pharmaceuticals, Inc., has an exclusive license in the United States to use the Suprax® trademark.

We plan to expand our family of pediatric products to help meet needs of children. Our focus is on in-house product development with our proprietary oral controlled release and taste masking platforms. Lupin Pharmaceuticals, Inc. is also open to marketing alliances, and to licensing/acquisitions.

API

Lupin is recognized as a leading manufacturer of cephalosporin API’s, with FDA approval to manufacture complex oral and injectable cephalosporins.Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of ACE-inhibitors and cholesterol reducing agents.Lupin’s capabilities in sterile processing, synthetic process development and fermentation skills coupled with its intellectual property strengths, puts the company in a very strong position to offer a diverse portfolio of niche API’s to its customers.

SHARE IN MARKET ANNUL

Lupin Limited (NSE:EQLUPIN)

Lupin Limited is amongst the top six pharmaceutical companies in India in terms of revenue. The Company is the world’s largest manufacturer of Tuberculosis drugs.

Business Overview

Headquartered in Mumbai, India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical

Ingredients(APIs)[1]The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs(Non-steroidal anti-inflammatory drugs)[1]

Net profit for Q4 FY 08-09 grew at 64.2% at Rs. 1574 million compared to Rs 959 million in Q4 FY 07-08.Net sales growth for Q4 FY 08-09 was 39% at Rs. 10434 million.[1]

Business and Financial Metrics

Lupin Limited's share holding pattern [4]Entity Percentage

Indian Promoters 50.62%Foreign Promoters 0.01% FII's 11.15% General Public9.21%Banks Fin. Inst. and Insurance09.76%Private Corporate Bodies1.48%NRI's/OCB's/Foreign Others2.90%Others0.13%

Business Segments

Formulations Active Pharamceutical Ingredients and Intermediates ROCE is comparable to the best in the segment at 33%[6]

\

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-3

http://www.wikinvest.com/wiki/ROCE


http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-latest



Competition

The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs.The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research & development, having clinical testing, marketing and distributing capabilities[7].Some of the main competitors of Lupin are:

Sun PharamceuticalsIndustires - It is No. 1 in India in speciality therapy areas like

psychiatry, neurology, cardiology, gastroenterology, diabetology and respiratory. [8].It has

brands in 30 markets worldwide and also has a generic presence in the U.S. with Caraco

Pharm Labs, Sun Pharmaceutical Industries Inc (subsidiary)[8]

Cipla - Cipla is a leader in the domestic retail pharmaceutical market. [9]It also exports raw

materials, intermediates, prescription drugs, over-the-counter products, and veterinary

products to some 180 countries around the world.[9]

GlaxoSmithKline - It is one of the oldest pharma companies in India and with a turnover of

Rs. 1500 crore is one of the market leaders(market share) in India with a share of 6.2 per

cent[10]Its main portfolios consists of anti- infectives, dermatologicals and pain management

drugs[11]

Dr. Reddy's Laboratories - It is a global pharmaceutical company with it's headquarters in

India and a presence in more than 100 countries.[12]In India it the biggest drug maker by


http://www.wikinvest.com/wiki/Dr._Reddy's_Laboratories


http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-gsk

http://www.wikinvest.com/wiki/GlaxoSmithKline

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-cipla

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-cipla

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-sun

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-sun


http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)?action=edit&section=5

sales[13]

Comparison with the competitors:

Financial metrics FY2008

Name Yr Ended Market Capitalization in Rs Cr Sales Turnover in Rs Cr Net Profit in Rs Cr

Mar '08 6,473.42 2,661.62 443.38

Sun Pharma Mar '08 26,975.87 2,427.35 1,014.04

Mar '08 17,947.66 4,293.95 701.43

GlaxoSmithKlinDec '07 9,992.41 1,762.64 576.57

DrReddys Labs Mar '08 9,662.53 3,428.40 475.22

Market Share on the basis of Retail Sales Due to high level of fragmentation none of the

Pharma Companies had more than 6% of the total market on the basis of the total retail sales. [15]

http://www.wikinvest.com/stock/Lupin_Limited_(NSE:EQLUPIN)#_note-mrkt


KEY DEVELOPMENTS FOR LUPIN PHARMACEUTICALS, INC.Lupin Pharmaceuticals, Inc. Gets US FDA Nod for Anti-Depressant

04/20/2010

Lupin Pharmaceuticals, Inc. announced that it has been granted final approval from the Food and Drug Administration (FDA) for the capsules in strengths of 75 mg, 100 mg, 125 mg and 150 mg. The drug is recommended for relieving depression symptoms. Lupin's Imipramine Pamoate capsules are generic equivalent of Mallinckrodt's Tofranil-PM. The drug had an annual sales of about $39 million for the year ended December, 2009.

Lupin Receives FDA Tentative Approval for Eszopiclone Tablets

03/22/2010

Lupin Pharmaceuticals, Inc. announced that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA). The company's Eszopiclone tablets are the AB-rated generic equivalent of Sepracor's LUNESTAR tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the twelve months ended

Documents

PROJECT ON LUPIN PHRMA